The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity

Clinical Cancer Research

Volumn 4, Issue 9, 1998, Pages 2027-2037

  Frei III, Emil ^a   Elias, Anthony ^a   Wheeler, Catherine ^a   Richardson, Paul ^a   Hryniuk, William ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CHLORMETHINE; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; PREDNISONE; PROCARBAZINE; THIOTEPA; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; FEMALE; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HORMONE DEFICIENCY; HUMAN; MALE; NEUROTOXICITY; PRIORITY JOURNAL; SOLID TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASMS;

EID: 0031663591     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Thomas, E. D. Current status of bone marrow transplantation. Transplant. Proc., 17: 428, 1985.
2. Frei, E., III. Combination cancer therapy: Presidential Address. Cancer Res., 32: 2593, 1972.
3. Frei, E., III, and Antman, K. H. Combination chemotherapy, dose and schedule. In: J. F. Holland, E. Frei III, R. C. Bast, Jr., D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.), Cancer Medicine, Ed. 4, pp. 817-837. Philadelphia: Williams & Wilkins, 1997.
4. Frei, E., III, and Canellos, G. P. Dose: a critical factor in cancer chemotherapy. Am. J. Med., 69: 585-594, 1980.
5. Schnipper, L. E. Clinical implications of tumor-cell heterogeneity. N. Engl. J. Med., 314: 1423-1434, 1986.
6. Frei, E., III. Pathobiology of cancer. Sci. Am., 12: 1-21, 1988.
7. Frei, E., III. Curative cancer chemotherapy. Cancer Res., 45: 6523-6532, 1985.
8. Holland, J. F., Frei, E., III, Bast, R. C., Jr, Kufe, D. W., Morton, D. L., and Weichselbaum, R. R. (eds.). Cancer Medicine, Ed. 4. Philadelphia: Williams & Wilkins, 1997.
9. V. DeVita, S. Hellman, and S. Rosenberg (eds.). Cancer: Principles and Practice of Oncology, Ed. 3. New York: J. B. Lippincott Co., 1989.
10. Canellos, G. Hodgkin's disease management. In: G. P. Canellos, T. A. Lister, and J. L. Sklar (eds.), The Lymphomas, p. 314. Philadelphia: W. B. Saunders Co., 1998.
11. J. Harris, M. Lippman, M. Morrow, and S. Hellman (eds.), Diseases of the Breast. Philadelphia: J. B. Lippincott Co., 1996.
12. Wood, W. C., Budman, D. R., Korzun, A. H., et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N. Engl. J. Med., 330: 1253-1259, 1994.
13. Freireich, E. J., Schmidt, P. J., Schneiderman, M. A., and Frei, E., III. A comparative study of the effect of transfusion of fresh and preserved whole blood on bleeding in patients with acute leukemia. N. Engl. J. Med., 260: 6, 1959.
14. Anderson, K. C. Hematologic complications and blood bank support. In: J. F. Holland, E. Frei III, R. C. Bast, Jr., D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.), Cancer Medicine, Ed. 4, pp. 3155-3177. Philadelphia: Williams & Wilkins, 1997.
15. Kessinger, A. Reestablishing hematopoiesis with peripheral blood stem cells. In: J. Armitage and K. Antman (eds.), High Dose Cancer Therapy, Ed. 2, pp. 196-210. Baltimore: Williams & Wilkins, 1995.
16. Muss, H. B., Thor, A. D., Berry, D. A., et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med., 330: 1260-1266, 1994.
17. Fisher, B., Fisher, E. R., Redmond, C., and participating NSABP investigators. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J. Clin. Oncol., 4: 929, 1986.
18. Bonadonna, G., Brusamolino, E,. Valagussa, P., Rossi, A., Brugnatelli, L., Brambilla, C., De Lena, M., Tancini, G., Bajetta, E., Musumeci, R., and Veronesi, U. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med., 294: 405, 1976.
19. Bonadonna, G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res., 52: 2127, 1992.
20. Osborne, C. K., Clark, G. M., and Ravdin, P. M. Adjuvant systemic therapy of primary breast cancer. In: J. Harris, M. Lippman, M. Morrow, and S. Hellman (eds.). Diseases of the Breast, pp. 548-578. Philadelphia: Lippincott-Raven, 1996.
21. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
22. Fung, C. Y., and Fisher, D. Apoptosis and p53. Critical determinants of outcome in radiation and chemotherapy. J. Clin. Oncol., 13: 808-811, 1995.
23. Kobayashi, H., Man, S., Graham, C. H., Kapitain, S. J., Teicher, B. A., and Kerbell, R. S. Acquired multicellular resistance to alkylating agents in cancer. Proc. Natl. Acad. Sci. USA, 90: 3294-3298, 1993.
24. Schmaltz, C., Harrigan Hardenbergh, P., Wells, A., and Fisher, D. E. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol. Cell. Biol., 18: 2845-2854, 1998.
25. Hryniuk, W. M. The importance of dose intensity in the outcome of chemotherapy. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.). Important Advances in Oncology, p. 121. Philadelphia: J. B. Lippincott Co., 1988.
26. Levin, L., and Hryniuk, W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J. Clin. Oncol., 5: 756-757, 1987.
27. Lacher, M. J., and Durant, J. R. Combined vinblastine and chlorambucil therapy of Hodgkin's disease. Ann. Intern. Med., 62: 468-476, 1965.
28. Frei, E., III, DeVita, V. T., Moxley J. H., and Carbone, P. P. Approaches to improving the chemotherapy of Hodgkin's disease. Cancer Res., 26: 1284-1289, 1966.
29. DeVita, V. T., Jr., Serpick, A. A., and Carbone, P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann. Intern. Med., 73: 881, 1970.
30. Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., Green, M. R., Gottlieb, A., and Peterson, B. A. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N. Engl. J. Med., 327: 1478-1484, 1992.
31. Pinkel, D. The Ninth Annual David Karnofsky Lecture: treatment of acute lymphocytic leukemia. Cancer (Phila.), 48: 1122-1128, 1979.
32. Holland, J. F. Breaking the cure barrier. Karnofsky Award Lecture. J. Clin. Oncol., 1: 75, 1983.
33. Foundations of Clinical Cancer Research. Perspective for the 21st century. A symposium to honor Emil J. Freireich, M. D., on the occasion of his 70th birthday. Clin. Cancer Res., 3: 2545-2734, 1997.
34. Sallan, S., and Weinstein, H. J. Childhood acute leukemia. In: D. Nathan and F. Oski (eds.), Hematology of Infancy and Childhood, Ed. 3, pp. 1028-1063. Philadelphia: W. B. Saunders Co., 1987.
35. Reiter, A., Schrappe, M., Ludwig, W. D., et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood, 84: 3122-3133, 1994.
36. Aur, R. J., Simone, J. V., Hustu, H. O., and Verzosa, M. S. A comparative study of central nervous system irradiation and intensive chemotherapy in childhood ALL. Cancer (Phila.), 29: 381, 1972.
37. Colvin, O. M. Alkylating agents and platinum antitumor compounds. In: J. F. Holland, E. Frei III, R. C. Bast, Jr., D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.), Cancer Medicine, Ed. 4, pp. 949-975. Philadelphia: Williams & Wilkins, 1997.
38. Frei, E., III, Freireich, E. J, Gehan, E., et al. Studies of sequential and combination antimetabolite therapy in acute leukemia 6 mercaptopurine and methotrexate. Blood, 18: 431-454, 1961.
39. Goldie, J. H. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin. Oncol., 14: 1, 1987.
40. Goldie, J. H., and Coldman, J. Application of theoretical models to chemotherapy protocol design. Cancer Treat. Rep., 70: 127, 1986.
41. Bonadonna, G., Valagussa, P., and Santoro, A. Alternating non-cross resistant combinations of MOPP and ABVD in stage IV Hodgkin's disease: a report of 8 year results. Ann. Intern. Med., 104: 739-740.
42. Jaffe, N., Frei, E., III, Traggis, D., and Bishop, Y. Adjuvant methotrexate and citrovorum factor treatment for osteosarcomas. N. Engl. J. Med., 291: 994-997, 1974.
43. Cortes, E. P., Holland, J. F., Wang, J. J., Sinks, L. F., Blom, J., Senn, H., Bank, A., and Glidewell, O. Amputation and Adriamycin primary osteosarcoma. N. Engl. J. Med., 2912: 998-1000, 1974.
44. Link, M. P., Goorin, A., Miser, A. M., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A., Kirkpatrick, J. A., Ayala, A., Shuster, J., Abelsonn, H. T., Simone, J., and Vietti, J. The effect of adjuvant chemotherapy on relapse free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med., 314: 1600-1608, 1986.
45. Marcove, R. C., and Rosen, G. En bloc resection for osteosarcoma. Cancer (Phila.), 45: 3040-3044, 1980.
46. Rosen, G., Forscher, C. A., Mankin, H. J., and Selch, M. T. Bone tumors. In: J. F. Holland, E. Frei III, R. C. Bast, Jr., D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.), Cancer Medicine, Ed. 4, pp. 2503-2557. Philadelphia: Williams & Wilkins, 1997.
47. Rosen, G., Marcove, R., Huvos, A. G., Caparros, B. I., Lane, J. M., Nirenberg, A., Cacavio, A., and Groshen, S. Primary osteosarcoma: eight year experience with adjuvant chemotherapy. J. Cancer Res. Clin. Oncol., 106 (Suppl.): 55-67, 1983.
48. Eilber, F., Giuliana, A., Eckardt, J., Patterson, K., Moseley, S., and Goodnight, J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J. Clin. Oncol., 5: 21-26, 1987.
49. Goorin, A., Abelson, H., and Frei, E., III. Osteosarcoma. Fifteen years later. N. Engl. J. Med., 313: 1637-1643, 1985.
50. Aisner, J., Korsun, A., Perloff, M., et al. A randomized comparison of CAF, VATH and VATH alternating with CMFVP for advanced breast cancer: a CALGB study. Proc. Am. Soc. Clin. Oncol., 7: 727, 1988.
51. Thomas, E. D., Clift, R. A., Fefer, A., et al. Marrow transplantation for the treatment of myelogenous leukemia. Ann. Intern. Med., 104: 155-163, 1986.
52. Thomas, E. D. Current status of bone marrow transplantation. Transplant. Proc., 17: 428, 1985.
53. Santos, G. Preparative regimen in bone marrow transplantation. Semin. Oncol., 20 (Suppl. 4): 4, 1993.
54. Santos, G. W., Tutschka, P. J., Brookmeyer, R., Saral, R., Beschorner, W. E., Bias, W. B., Braine, H. G., Burns, W. H., Elfenbein, G. J., Kaizer, H., Mellits, D., Sensenbrenner, L. L., Stuart, R. K., and Yeager, A. M. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphomide. N. Engl. J. Med., 309: 1347-1352, 1983.
55. Peters, W. P., Eder, J. P., Henner, W. D., Schryber, S., Wilmore, D., Finberg, R., Schoenfel, D., Bast, R., Gargone, B., Antman, K., Anderson, J., Anderson, K., Kruskall, M. S., Schnipper, L., and Frei, E., III. High-dose combination alkylating agents with autologous bone marrow support: a Phase I trial. J. Clin. Oncol., 4: 646-651, 1986.
56. Antman, K., Eder, J. P., and Frei, E., III. High-dose chemotherapy with bone marrow support for solid tumors. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Important Advances in Oncology, p. 221. Philadelphia: J. B. Lippincott Co., 1987.
57. Frei, E., III, Antman, K., Teicher, B., Eder, P., and Schnipper, L. Bone marrow autotransplantation for solid tumors: prospects. J. Clin. Oncol., 7: 515, 1989.
58. Antman, K., and Gale, R. R. Advanced breast-cancer: high dose chemotherapy and autotransplants. Ann. Intern. Med., 108: 570-574, 1988.
59. Schabel, F. M., Jr., Trader, M. W., Laster, W. R., Jr., Wheeler, G. P., and Witt, M. H. Patterns of resistance and therapeutic synergy among alkylating agents. Cancer Chemother. Pharmacol., 23: 200, 1978.
60. Frei, E., III, Cucchi, C., Rosowsky, A., Tantravahi, R., Bernal, S., Ervin, T. J., Ruprecht, R. M., and Haseltine, W. A. Alkylating agent resistance: in vitro studies in human tumor cell lines. Proc. Natl. Acad. Sci. USA, 82: 2158, 1985.
61. Fisher, R., Gaynor, E., Dahlbert, S., Oken, M., Grogan, T., Mize, E., Glick, J., and Coltman, C. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for non-Hodgkin's lymphoma. N. Engl. J. Med., 328: 1012, 1993.
62. Morrow, C. S., and Cowan, K. Drug resistance and its clinical circumvention. In: J. F. Holland, E. Frei III, R. C. Bast, Jr., D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.), Cancer Medicine, Ed. 4, pp. 799-815. Philadelphia: Williams & Wilkins, 1997.
63. Harris, C. C., and Holstein, M. Clinical implications of p53 tumor suppressor gene. N. Engl. J. Med., 329: 13-18, 1993.
64. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
65. Rao, L., Debbas, M., Sabbitini, P., Hockenberry, D., Korsmeyer, S., and White, E. The adenovirus E1A proteins induce apoptosis which is inhibited by the E1B, 19K and bcl-2 proteins. Proc. Natl. Acad. Sci. USA, 89: 7742-7746, 1992.
66. Chaudhary, P. M., and Roninson, I. B. Induction of multidrug resistance in human clones by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst. (Bethesda), 85: 632-639, 1993.
67. Surbone, A., Gilewski, T. A., and Norton, L. Cytokinetics. In: J. F. Holland, E. Frei, III, R. C. Bast, Jr., D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.), Cancer Medicine, Ed. 4, pp. 769-798. Philadelphia: Williams & Wilkins, 1997.
68. Kerr, J. F. R., Winterford, C. M., and Harmon, B. V. Apoptosis: its significance to cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
69. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 778: 539-542, 1994.
70. Graham, C. H., Kobayashi, H. Stankiewicz, K. S., Man, S., Kapitain, S. J., and Kerbel, R. S. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J. Natl. Cancer Inst. (Bethesda), 86: 975-982, 1994.
71. Potten, C. S. Interleukin 11 protects the clonogenic stem cells in murine small intestinal crypts from impairment of their reproductive capacity by radiation. Int. J. Cancer, 62: 356-361, 1995.
72. Niemeyer, C. M., and Sallan, S. E. Acute lymphoblastic leukemia. In: D. Nathan and F. Oski (eds.) Hematology of Infancy and Childhood, Ed. 4, pp. 1249-1287. Philadelphia: W. B. Saunders Co., 1993.
73. Perez, D. J., Harvey, V. J., Robinson, B. A., Atkinson, C. H., Dady, P. J., Kirk, A. R., Evans, B. D., and Chapman, P. J. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J. Clin. Oncol., 9: 2148-2152, 1991.
74. Kolaric, K., and Roth, A. Phase II clinical trial of cis-dichlorodiammineplatinum (Cis DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother. Pharmacol., 11: 108-112, 1983.
75. Rubens, R. D., Knight, R. K., and Hayward, J. L. Chemotherapy of advanced breast cancer: A controlled randomized trial of cyclophosphamide versus a four-drug combination. Br. J. Cancer, 32: 730-736, 1975.
76. Ansfield, F., Klotz, J., Nealon, T., Ramirez, G., Minton, J., Hill, G., Wilson, W., Davis, H., Jr., and Cornell, G. A Phase III study comparing the clinical utility of four regimens of 5-fluorouracil. A preliminary report. Cancer (Phila.), 39: 34-40, 1977.
77. Sears, M. E., Tucker, W., Coltman, C. A., et al. Effectiveness of various dosage schedules of methotrexate in advanced breast carcinoma. Cancer Chemother. Rep., 53: 93, 1969.
78. Carter, S. K. Single and combination nonhormonal chemotherapy in breast cancer. Cancer (Phila.), 30: 1543-1555, 1972.
79. Tannock, I. F., Boyd, N. F., DeBoer, G., Erlichman, C., Fine, S., Larocque, G., Mayers, C., Perrault, D., and Sutherland, H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J. Clin. Oncol., 6: 1377-1387, 1988.
80. Englesman, E., Klijn, J. C., Rubens, R. D., Wildiers, J., Beex, L. V., Nooij, M. A., Rotmensz, N., and Sylvester, R. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. Eur. J. Cancer, 27: 966-970, 1991.
81. Bezwoda, W. R, Seymour, L., and Dansey, R. D. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J. Clin. Oncol., 13: 2483-2489, 1995.